Cancer Management and Research最新文献

{"title":"Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.","authors":"Kevin C Miller, Issam Hamadeh, Carlyn Rose Tan","doi":"10.2147/CMAR.S441550","DOIUrl":"10.2147/CMAR.S441550","url":null,"abstract":"<p><p>Despite recent advancements, most patients with multiple myeloma eventually develop resistance to available treatments, highlighting the need for new therapeutic strategies. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a viable novel therapeutic target on myeloma cells, leading to the clinical development of talquetamab, the first GPRC5D-directed bispecific T-cell engager (TCE). Talquetamab was granted accelerated approval in August 2023 by the Food and Drug Administration. Besides expected short-term toxicities including cytokine release syndrome, neurotoxicity and cytopenias, talquetamab commonly causes adverse events involving the oral cavity, nails, and skin, which can negatively impact quality of life and in some cases lead to treatment discontinuation. Despite these pitfalls, talquetamab yields responses in most treated patients, which in a subset are durable. There are now several clinical trials investigating talquetamab in different clinical contexts in multiple myeloma, as well as in combination with other anti-myeloma agents. Beyond results from these prospective trials, better biologic understanding of resistance mechanisms to talquetamab and improved strategies to mitigate common toxicities are key questions as talquetamab finds its place in the treatment of multiple myeloma.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"743-756"},"PeriodicalIF":2.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional Treatment Strategies for Carotid Blowout Syndrome After Radiotherapy for Nasopharyngeal Carcinoma.","authors":"Zhipeng Lin, Jianqiao Chen, Xugong Zou, Jian Zhang, Dabei Huang","doi":"10.2147/CMAR.S509063","DOIUrl":"10.2147/CMAR.S509063","url":null,"abstract":"<p><strong>Background: </strong>Carotid blowout syndrome (CBS) is a life-threatening complication that can occur after radiotherapy in nasopharyngeal carcinoma (NPC) patients, resulting in catastrophic hemorrhage. Endovascular treatments, including coil embolization and stent grafting, have become standard options for managing CBS. Recent studies suggest that individualized approaches based on aneurysm location and vascular condition may further reduce recurrence and complications. This study aims to evaluate the efficacy, safety, and outcomes of these treatments in NPC patients with CBS.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 46 NPC patients who developed CBS following radiotherapy and underwent endovascular intervention at Zhongshan People's Hospital between January 2016 and July 2023. Outcomes such as immediate hemostasis, rebleeding rates, complications, and 1-year survival were analyzed.</p><p><strong>Results: </strong>Among the 46 patients, 29 received coil embolization and 17 underwent stent grafting. Immediate hemostasis was achieved in all cases (100%). The 1-year rebleeding rate was 8.6% (4/46), and the overall complication rate was 8.6% (4/46), with cerebral infarctions being the primary concern. Coil embolization is associated with lower rebleeding rates, while stent grafting preserves arterial patency better. The 1-year survival rate was 89.1% (41/46).</p><p><strong>Conclusion: </strong>Endovascular interventions, including coil embolization and stent grafting, are effective in managing CBS in NPC patients after radiotherapy. Future research should focus on refining patient selection criteria and optimizing long-term outcomes.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"757-765"},"PeriodicalIF":2.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of EFNAs in Shaping the Tumor Immune Microenvironment and Their Impact on Pancreatic Adenocarcinoma Prognosis.","authors":"Yu-Chao Li, Lu Zhang, Yi-Ting Wang, Hao Hu, Ze-Yu Zhang, Qian-Qian Nie, Chang-Jing Zuo","doi":"10.2147/CMAR.S502401","DOIUrl":"10.2147/CMAR.S502401","url":null,"abstract":"<p><strong>Purpose: </strong>Due to the highly heterogeneous and immunosuppressed tumor microenvironment (TME), pancreatic adenocarcinoma (PAAD) has limited therapeutic options and an abysmal prognosis. Ephrin A 1-5 (EFNA1-5) have been shown to regulate tumorigenesis and metastasis in various cancers, but its role in PAAD remains unclear.</p><p><strong>Methods: </strong>We comprehensively analyzed <i>EFNA</i> gene expression levels in pan-cancer and PAAD using the GEPIA and HPA databases. Then, we assessed the prognostic value of EFNA1-5 using the Kaplan-Meier plotter and nomogram model. Further exploration of the association of EFNA1-5 with clinicopathological features of PAAD used information from the UALCAN database, and the TIMER dataset was used to reveal the correlation between EFNA1-5 and the tumor immune microenvironment (TIME) of pancreatic cancer. In addition, cBioPortal Databases, GSEA, and GSCALite were used to explore gene changes, protein interactions, and biological functions. Finally, the oncogenic effect of EFNA5 was verified in vivo and in vitro.</p><p><strong>Results: </strong>The expression levels of EFNA1-5 were significantly upregulated in PAAD. The expression of EFNA1/3/4/5 were significantly associated with overall survival (OS) and relapse-free survival (RFS) in PAAD patients. The high expression of EFNA2-5 were related to poor clinical features, such as higher tumor stage or grade and a wider range of lymph node metastasis. EFNA1-5 were closely associated with immune cell infiltration, CAFs, and MDSCs expression. Furthermore, EFNA5 is an independent risk factor for poor prognosis in PAAD patients, and it can promote the malignant progression of pancreatic cancer in vitro and in vivo.</p><p><strong>Conclusion: </strong>Differential expression of EFNA1-5 is associated with TIME in pancreatic cancer, predicts different survival outcomes, and maybe a novel prognostic marker reflecting an immunosuppressive state and a potential therapeutic target.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"693-712"},"PeriodicalIF":2.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Habitat Analysis in Tumor Imaging: Advancing Precision Medicine Through Radiomic Subregion Segmentation.","authors":"Ling Xiao Wu, Ning Ding, Yi Ding Ji, Yi Chi Zhang, Meng Juan Li, Jia Cheng Shen, Hai Tao Hu, Long Jin, Sheng Nan Yin","doi":"10.2147/CMAR.S511796","DOIUrl":"10.2147/CMAR.S511796","url":null,"abstract":"<p><p>Radiomics received a lot of attention because of its potential to provide personalized medicine in a non-invasive manner, usually focusing on the analysis of the entire lesion. A new method called habitat can identify subregional phenotypic changes within the lesion, thereby improving the ability to distinguish heterogeneity. The clustering method can be applied to multiple measurement parameters to separate different tumor habitats by segmentation. A data-driven repeatable voxel clustering method to identify subregions reflecting live tumors will be valuable for clinical diagnosis and further treatment. In this review, we aim to briefly summarize the widely used cluster analysis algorithms in subregion segmentation and the application of habitat analysis in tumor imaging. By analyzing many literatures, the commonly used K-means algorithm and other algorithms such as hierarchical clustering and consensus clustering are summarized. By identifying intratumoral heterogeneity, the key findings of habitat analysis in oncology are described, such as tumor differentiation, grading, and gene expression status. The latest progress and innovations in predicting tumor therapeutic effects and prognosis using habitat analysis are reviewed, including multimodal imaging data fusion, integration with artificial intelligence technologies, and non-invasive diagnostic methods. The limitations and challenges of habitat analysis in tumor imaging are also discussed, such as dependence on image quality and imaging techniques, insufficient automation and standardization, difficulties in biological interpretation, and lack of clinical validation. Finally, future directions for increasing the level of automation and standardization of habitat analysis to improve its accuracy and efficiency and reduce reliance on expert intervention are proposed. Habitat analysis represents a significant advancement in radiomics, offering a nuanced understanding of tumor heterogeneity. By leveraging sophisticated clustering algorithms and integrating multimodal imaging data, habitat analysis has the potential to transform clinical decision-making, enabling more precise diagnostics and personalized treatment strategies, ultimately advancing the field of precision medicine.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"731-741"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Fatty Pancreas Disease and Pancreatic Diseases, Perioperative Complications of Pancreatic Surgery.","authors":"Zhejing Wu, Jingdong Li","doi":"10.2147/CMAR.S508567","DOIUrl":"10.2147/CMAR.S508567","url":null,"abstract":"<p><p>Fatty pancreas disease (FPD) refers to excessive fat accumulation and fat infiltration in pancreatic tissue. Factors such as obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), and alcohol consumption can contribute to the development of FPD. Patients with FPD typically lack obvious clinical symptoms or signs, and diagnosis primarily relies on imaging techniques. Currently, there is limited attention to this disease both domestically and internationally. FPD is closely associated with pancreatic-related diseases (eg, diabetes, pancreatitis, pancreatic cancer). Pancreatic cancer, characterized by high mortality and low survival rates, has been linked to FPD in terms of its occurrence, progression, and patient prognosis. FPD is considered a potential early clinical manifestation of pancreatic cancer and may promote distant metastasis. However, the mechanisms by which FPD contributes to pancreatic carcinogenesis remain unclear. Additionally, Studies have found that FPD can lead to perioperative complications (postoperative pancreatic fistula, postoperative nonalcoholic fatty liver, endoscopic retrograde cholangiopancreatography pancreatitis), which are closely related to the prognosis of patients after pancreatic surgery.Although FPD is challenging to diagnose, its instability allows for clinical management through early dietary interventions, oral medications, and, when necessary, bariatric surgery to alter disease progression. Whether targeting adipocytes, lipid metabolism, or adipocyte-related cytokines could serve as novel intervention strategies for pancreatic cancer remains a critical area for further investigation.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"723-730"},"PeriodicalIF":2.5,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S100 Protein Family in Lung Cancer: an Updated Narrative Review.","authors":"Ting Wang, Rui Liu","doi":"10.2147/CMAR.S508047","DOIUrl":"10.2147/CMAR.S508047","url":null,"abstract":"<p><p>The S100 protein family comprises 25 known members that modulate variously basic biological behaviors of cells by binding Ca²⁺ and activating Ca²⁺-signaling pathways. As the primary cause of cancer-related death, lung cancer is closely associated with several S100 proteins, like S100A2, S100A4, S100A6, S100A8/9, etc. Notably, the functions and mechanisms of different S100 proteins vary in every sub-type of lung cancer. Overall speaking, the abnormal expression of S100 proteins is predominantly observed in lung adenocarcinoma, while their roles are limited in small-cell lung cancer. This review, which presents an update on our previously published review of S100 proteins in lung cancer (2021), aims to enable readers having a deeper understanding of the roles of different S100 proteins in three main sub-types of lung cancer, as well as to facilitate their future researches. It focuses on relevant studies examining the functions of S100 proteins in lung adenocarcinoma, squamous carcinoma, and small-cell lung cancer. This review was conducted based on this standard, and provides a comprehensive evaluation of the literature review on S100 proteins as well as enhances understanding of the relationship between S100 proteins and every sub-type of lung cancer from a new perspective.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"713-722"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of SETDB2 in Clear Cell Renal Cell Carcinoma: Linking Immune Infiltration, Cuproptosis, and Tumor Suppression.","authors":"Si Hao Lu, Kui Lui, Yue Qian, Wei Ye Zhou, Ying Ying Mu, Wei Zhang","doi":"10.2147/CMAR.S499771","DOIUrl":"10.2147/CMAR.S499771","url":null,"abstract":"<p><strong>Background: </strong>Clear cell renal cell carcinoma (ccRCC) is a relatively frequently diagnosed form of urological cancer that is highly malignant and associated with high rates of patient mortality. At present, there are few effective options for treating advanced cases of ccRCC, emphasizing the need to establish novel biomarkers and targets suitable for therapeutic intervention. SET domain bifurcated histone lysine methyltransferase 2 (SETDB2) belongs to the Su(var)3-9 subfamily of methyltransferases and has been linked to various forms of cancer, but the role it plays in ccRCC remains to be fully established.</p><p><strong>Methods: </strong>Data on SETDB2 expression were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Functional enrichment analyses were then used to probe the putative role that SETDB2 plays in the onset of ccRCC. The Gene Set Cancer Analysis (GSCA) platform and molecular docking analysis were utilized to investigate the relationship between gene expression and drug sensitivity. In the end, the core target and the active molecule were both given the green light for a molecular docking investigation. Functional assays and Western blotting performed with ccRCC cell lines were employed for the validation of the findings from these predictive analyses.</p><p><strong>Results: </strong>SETDB2 downregulation was observed in ccRCC, and lower levels were found to linked with poor patient outcomes. Lower SETDB2 levels were associated with worse overall, progression-free, and disease-specific survival. In Functional enrichment analyses, SETDB2 was predicted to regulate key ccRCC development-associated pathways. SETDB2 levels were also significantly associated with cuproptosis induction in KIRC tissues, while in immune cell infiltration analyses, SETDB2 expression was linked with immune responses within the tumor microenvironment. Functional experiments conducted with ccRCC cell lines unveiled molecular mechanisms through which SETDB2 appears to be capable of inhibiting the development of ccRCC.</p><p><strong>Conclusion: </strong>Together, these analyses highlight the utility of SETDB2 as a prognostic biomarker in ccRCC. The interactions and associated pathways detected through these analyses provide unique insight into the potential functions of SETDB2 in this cancer type, providing an evidence base for future studies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"675-692"},"PeriodicalIF":2.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of AHCY Expression in Bladder Urothelial Carcinoma: A Bioinformatics and Experimental Analysis.","authors":"Shaorui Niu, Xiaozhe Zheng, Yuyang Yao, Yue Dong, Yupan Hu, Zhiyang Xiao, Jiaxue Yang, Chengli Jiang, Xin Zou, Zihao Zou, Pang Yang","doi":"10.2147/CMAR.S491044","DOIUrl":"10.2147/CMAR.S491044","url":null,"abstract":"<p><strong>Background: </strong>Although adenosylhomocysteinase (AHCY) is crucial to the oncogenesis and growth of some cancers, it is unknown how this affects bladder urothelial carcinoma (BLCA). Investigating the variations in AHCY expression in BLCA and examining the relationship between AHCY expression and BLCA patient prognosis were the goals of this investigation.</p><p><strong>Methods: </strong>By leveraging The Cancer Genome Atlas (TCGA) database, we undertook a meticulous examination of AHCY expression levels, juxtaposing them between BLCA and normal tissues. Subsequently, Kaplan-Meier analysis and COX regression and nomogram was used to assess the effect of AHCY on the survival of BLCA patients. We further elaborated on the possible enriched pathways of AHCY and its immune relevance. In addition, we employed si-RNA technology to downregulate the AHCY gene expression and subsequently utilized quantitative real-time PCR (qRT-PCR), CCK-8, cell scratch assays, and Transwell migration assays to validate the pivotal role of AHCY in BLCA.</p><p><strong>Results: </strong>The expression of AHCY was associated with various types of malignancies (including BCLA). In BLCA cancer tissues, there was an observed upregulation of AHCY expression in comparison to paracancerous tissues. Increased expression of AHCY was linked to decreased overall survival (OS), clinical stage, N stage, and T stage in individuals with BLCA. The functional enrichment of AHCY related genes mainly involves biological processes such as rRNA metabolic processes, proteasome activity, and cell cycle regulation, etc. Furthermore, AHCY showed significant associations with m6A related genes and infiltration of immune cells (Especially for Th2 cells and T-gd lymphocytes). In vitro functional experiments substantiated that the inhibition of AHCY effectively suppresses the growth, migration, and invasion of bladder cancer cells.</p><p><strong>Conclusion: </strong>This study provides novel insights into the role of AHCY in BLCA, which holds significant potential to contribute towards advancing the diagnosis and treatment of BLCA in the future.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"661-673"},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the Evaluation Value of Combined Magnetic Resonance Imaging and Ultrasound Blood Flow Parameters in Cervical Lymph Node Metastasis of Thyroid Cancer.","authors":"Xiaosong Sun, Zhengchao Wei, Yiqiang Luo, Ming Wang","doi":"10.2147/CMAR.S505730","DOIUrl":"10.2147/CMAR.S505730","url":null,"abstract":"<p><strong>Background: </strong>Thyroid cancer exhibits the highest cervical lymph node metastasis rate (20-50%) among head and neck malignancies, with occult metastasis occurring in 30-80% of papillary carcinoma cases. However, conventional single-modality imaging faces certain challenges: MRI has limited sensitivity for detecting micro-metastases (<2mm), while Doppler ultrasound may overlook metastases in isoechoic lymph nodes. Therefore, it is crucial to evaluate the diagnostic value of combining MRI and CDUS. This study aims to retrospectively analyze the diagnostic value of combining MRI and CDUS blood flow parameters in detecting cervical lymph node metastasis in thyroid cancer and to compare the diagnostic performance with MRI or CDUS alone.</p><p><strong>Objective: </strong>To analyze the evaluation value of combining MRI and color Doppler ultrasound (CDUS) blood flow parameters in detecting cervical lymph node metastasis of thyroid cancer, particularly for occult metastases.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 263 thyroid cancer patients (June 2022-June 2024). Diagnostic consistency between MRI, CDUS parameters (resistive index, pulsatility index, vascular patterns) and pathology were compared. Multimodal evaluation criteria were established: (1) MRI positive signs (lymph node diameter >8mm, cystic change, enhancement heterogeneity) (2) CDUS thresholds (RI≥0.75, PI≥1.25 with chaotic vascularity).</p><p><strong>Results: </strong>Among 263 patients, 98 had pathologically confirmed metastases. CDUS showed higher consistency with pathology (Kappa=0.783) than MRI (Kappa=0.645). Combined modality achieved 94.9% sensitivity vs 86.7% (CDUS) and 78.6% (MRI), with accuracy improving from 82.1%/75.3% to 89.4% (P<0.05). Notably, 12/22 occult metastases (≤3mm) were only detected by combined approach.</p><p><strong>Conclusion: </strong>The synergistic combination leverages MRI's structural characterization and CDUS's hemodynamic sensitivity, effectively overcoming single-modality limitations in detecting micro-metastases. This dual-assessment protocol addresses thyroid cancer's propensity for early lymphatic spread, providing critical preoperative staging guidance.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"651-659"},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety and Efficacy of Anticancer Therapy in Breast Cancer Patients with Liver Cirrhosis.","authors":"Zhan-Yi Li, Yuan Teng, Chen-Meng Long, Ren-Bin Liu, Yu Liu","doi":"10.2147/CMAR.S503109","DOIUrl":"10.2147/CMAR.S503109","url":null,"abstract":"<p><strong>Purpose: </strong>Special populations are not enrolled in randomized clinical trials, and their safety and efficacy of anticancer therapy are not well described. We aimed to assess the safety and efficacy of anticancer therapy in breast cancer (BC) patients with cirrhosis.</p><p><strong>Patients and methods: </strong>We performed a retrospective case-control study (1:5) to assess the adverse events (AEs) morbidity and mortality of anticancer therapy in BC patients with cirrhosis based on a review of patients' medical records.</p><p><strong>Results: </strong>We included 26 BC patients with cirrhosis and 130 matched BC patients without cirrhosis. Postoperative morbidity was higher in the group with cirrhosis (26.9% vs 6.9%, P = 0.007) when postoperative mortality was not significance (3.8% vs 0%, P = 0.167). Liver toxicity (73.1% vs 26.9%, P < 0.001) was more frequent in the group with cirrhosis. The incidence of disruption and mortality during chemotherapy was higher in the group with cirrhosis (46.2% vs 3.1%, P < 0.001 and 15.4% vs 0%, P = 0.001, respectively). The 2-year recurrence rate and 2-year metastasis rate were higher in the group with cirrhosis (19.0% vs 3.8%, P = 0.022 and 23.8% vs 6.9%, P = 0.028). Cirrhosis was the risk factor for liver metastasis (OR: 17.326, 95% CI: 2.164-138.707, P=0.007).</p><p><strong>Conclusion: </strong>It is safe for BC patients with compensated cirrhosis to accept surgery. But they are vulnerable to AEs, disruptions and death during chemotherapy and have poor prognosis. Multidisciplinary cooperation before therapy and closely monitoring AEs during therapy are critical. Attention should be given to optimize the prognosis of special BC patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"639-650"},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}